CGON — Stock Film
STOCK FILMSCENE 1/11CGON · $77.61
Stock Expert AI presents
CGON
CG Oncology Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
CG Oncology Inc. A quick introduction.

On the stock market since 2024, it operates in the world of health and science. It has 142 employees. Now — the numbers.

on the stock market since 2024
142 employees
$6.6B market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $41.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

THE SALES TREND
Sales have been shrinking.

An average decline of 21% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$10.4M
2021
$191K
2022
$204K
2023
$1.1M
2024
$4M
2025
In the vault right now:
$0
DEBT: $7.0M
At this pace, that money lasts about 4.6 years.

Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
18
very weak

Clearly below the class average.

FINANCIAL STRENGTH
97
very strong

Debt is low and cash is strong; the finances stand solid.

VALUATION
49
weak

Clearly below the class average.

GROWTH
23
very weak

Clearly below the class average.

PRICE MOMENTUM
88
very strong

The stock has been running stronger than the market lately.

WORTH WATCHING

Business Quality: Profit power and business quality trail similar companies in the sector.

Growth: Sales growth trails the sector average.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Heavy investment in the future10/10
Few are betting against it10/10
WEAK SPOTS
Each sale is made at a loss3/10
WORTH WATCHING

Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.

THE FIVE-YEAR JOURNEY
Bumpy, but the direction is up.

The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.

1
THE BRIGHT SIDE · 1/2
The product is selling

Sales run at $4.0M a year. A small number, but proof the product has real buyers.

2
THE BRIGHT SIDE · 2/2
Strong cash, light debt

There is $742.2M in the vault; even if every debt were paid off, $735.1M would remain.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $161.0M against $4.0M in annual sales.

2
THE RISKS · 2/3
The business trails its class

Measured against its sector, the quality of the business sits below the class average. Report-card grade: 18/100.

3
THE RISKS · 3/3
Growth trails the sector

The growth engine is running at low revs right now. Report-card grade: 23/100.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, CGON sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: CGON is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 20, 2026 · stockexpertai.com · Stock Film